🇺🇸 FDA
Pipeline program

IASO104

IIT2025081

Phase 1 mab active

Quick answer

IASO104 for Relapsed/Refractory Multiple Myeloma (RRMM) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Relapsed/Refractory Multiple Myeloma (RRMM)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials